A promising triple-action medication is making headlines, but understanding the evidence and the safety considerations matters more than the hype.
The big picture
Retatrutide is an investigational once-weekly injectable medication developed by Eli Lilly for obesity and related conditions. Early and Phase 3 findings have generated excitement because substantial weight reduction has been observed in clinical trials. However, as of October 2026, retatrutide is not FDA-approved.
What makes retatrutide different?
Many familiar weight-management medications target GLP-1, a hormone involved in appetite and blood-sugar regulation. Tirzepatide targets two hormone receptors (GLP-1 and GIP). Retatrutide activates three: GLP-1, GIP, and glucagon receptors. Researchers are studying how this combination influences appetite, glucose regulation, and energy balance. You may see the nickname “GLP-3” online, but that is not an official medical drug class.
What does the research actually show?
In the Phase 3 TRIUMPH-1 trial, 2,339 adults with obesity and without diabetes were studied for 80 weeks. In one analysis, average weight reductions were 17.6%, 23.7%, and 25.0% with the 4 mg, 9 mg, and 12 mg groups, compared with 3.9% for placebo. Another analysis reported 28.3% average weight reduction with 12 mg, or approximately 70 pounds in that study population. These numbers reflect different statistical approaches, not contradictory results.
The trial also evaluated outcomes related to knee osteoarthritis symptoms and obstructive sleep apnea. Other Phase 3 research in adults with type 2 diabetes has reported improvements in weight and A1C. These are encouraging findings, but no clinical trial can predict an individual person’s results.
How does it compare with current medications?
| Medication | Targets | Regulatory status (Oct 2026) |
|---|---|---|
| Semaglutide (Wegovy) | GLP-1 | FDA-approved for certain uses |
| Tirzepatide (Zepbound) | GLP-1 + GIP | FDA-approved for certain uses |
| Retatrutide | GLP-1 + GIP + glucagon | Investigational; not FDA-approved |
Comparing weight-loss percentages from different trials can be misleading: study populations, doses, durations, and statistical methods vary. Direct comparative trials are needed to establish relative effectiveness and safety.
What about side effects and safety?
The most frequently reported side effects have been gastrointestinal, including nausea, vomiting, diarrhea, and constipation. Tolerability may vary by dose. Researchers continue to evaluate longer-term safety, and the final benefit–risk profile will require regulatory review.
People considering any weight-management medicine should review their medical history, current medications, pregnancy plans, and relevant contraindications with a qualified healthcare professional. Important warnings and restrictions differ by product; they should not be assumed to be identical for an investigational medication.
An important warning about products sold online
The FDA has warned against unapproved retatrutide products marketed online, including products labeled “research use only.” These products may be of unknown quality and could pose health risks.
Why protecting muscle matters during weight management
Weight change does not tell the whole story. During significant weight loss, some lean mass may also be lost. Preserving strength and physical function is an important part of long-term metabolic health. A comprehensive care plan may include individualized nutrition, adequate protein, age- and ability-appropriate resistance exercise, sleep, and periodic monitoring of body composition when clinically useful.
The objective is not simply a lower number on the scale. It is better overall health, sustainable habits, and maintaining strength as health goals evolve.
What can patients do now?
While retatrutide remains in development, established evidence-based options for obesity care already exist. A licensed professional can help review current treatment options, nutrition and activity habits, medical history, and any appropriate follow-up testing. The best plan is individualized and considers effectiveness, safety, tolerability, access, and the patient’s goals.
The Re Wellness Hub approach
At Re Wellness Hub, our philosophy is preventive, not reactive. We focus on sustainable wellness and long-term metabolic health, not a quick fix. If you are interested in learning about current evidence-based weight-management options, schedule a consultation to discuss a personalized plan with a licensed practitioner.
Restore. Revitalize. Renew.
Educational information only. This article is not medical advice. FDA approval status and evidence may change after publication.
References and further reading
- Jastreboff AM, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. New England Journal of Medicine. Published September 29, 2026. doi:10.1056/NEJMoa2604169.
- Eli Lilly. TRIUMPH-1 Phase 3 topline results, May 21, 2026.
- Eli Lilly. TRIUMPH-2 and TRIUMPH-3 results, July 23, 2026.
- U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.